Classic psychedelics, health behavior, and physical health.

BMI behavior health psilocybin psychedelics

Journal

Therapeutic advances in psychopharmacology
ISSN: 2045-1253
Titre abrégé: Ther Adv Psychopharmacol
Pays: England
ID NLM: 101555693

Informations de publication

Date de publication:
2022
Historique:
received: 18 02 2022
accepted: 26 09 2022
entrez: 5 12 2022
pubmed: 6 12 2022
medline: 6 12 2022
Statut: epublish

Résumé

Preliminary evidence suggests that classic psychedelics may be effective in the treatment of some psychiatric disorders, yet little remains known about their effects on health behavior and physical health. The purpose of this study was to investigate associations of lifetime classic psychedelic use and psychological insight during one's most insightful classic psychedelic experience with health behavior and physical health. Using data representative of the US population with regard to sex, age, and ethnicity ( Lifetime classic psychedelic use was associated with more healthy tobacco-related and diet-related behavior ( Although these results cannot demonstrate causality, they suggest that psychological insight during a classic psychedelic experience may lead to positive health behavior change and better physical health in some domains, in particular in those related to weight management.

Sections du résumé

Background UNASSIGNED
Preliminary evidence suggests that classic psychedelics may be effective in the treatment of some psychiatric disorders, yet little remains known about their effects on health behavior and physical health.
Objectives UNASSIGNED
The purpose of this study was to investigate associations of lifetime classic psychedelic use and psychological insight during one's most insightful classic psychedelic experience with health behavior and physical health.
Methods UNASSIGNED
Using data representative of the US population with regard to sex, age, and ethnicity (
Results UNASSIGNED
Lifetime classic psychedelic use was associated with more healthy tobacco-related and diet-related behavior (
Conclusion UNASSIGNED
Although these results cannot demonstrate causality, they suggest that psychological insight during a classic psychedelic experience may lead to positive health behavior change and better physical health in some domains, in particular in those related to weight management.

Identifiants

pubmed: 36465958
doi: 10.1177/20451253221135363
pii: 10.1177_20451253221135363
pmc: PMC9716448
doi:

Banques de données

figshare
['10.6084/m9.figshare.21490059.v1']

Types de publication

Journal Article

Langues

eng

Pagination

20451253221135363

Subventions

Organisme : NCCIH NIH HHS
ID : K23 AT010879
Pays : United States

Informations de copyright

© The Author(s), 2022.

Déclaration de conflit d'intérêts

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: P.S.H. is on the scientific advisory board of Bright Minds Biosciences Ltd., Eleusis Benefit Corporation, and Reset Pharmaceuticals Inc. O.S. and R.C. are co-founders of Eudelics AB.

Références

J Psychopharmacol. 2016 Dec;30(12):1268-1278
pubmed: 27578767
Alcohol Clin Exp Res. 2007 Jul;31(7):1208-17
pubmed: 17451397
Curr Drug Abuse Rev. 2014;7(3):157-64
pubmed: 25563443
J Psychopharmacol. 2019 Sep;33(9):1088-1101
pubmed: 31084460
J Am Coll Health. 2017 Oct;65(7):492-501
pubmed: 28641040
J Psychoactive Drugs. 2019 Apr-Jun;51(2):135-145
pubmed: 30732540
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
J Psychopharmacol. 2016 Dec;30(12):1279-1295
pubmed: 27856683
Neuropharmacology. 2022 Aug 15;214:109127
pubmed: 35577136
J Psychopharmacol. 2021 Apr;35(4):437-446
pubmed: 33427007
Nicotine Tob Res. 2012 Jan;14(1):75-8
pubmed: 22025545
J Psychoactive Drugs. 2020 Sep-Oct;52(4):289-299
pubmed: 32529966
J Psychopharmacol. 2021 Apr;35(4):447-452
pubmed: 33719688
J Psychopharmacol. 2015 Nov;29(11):1182-90
pubmed: 26442957
J Psychoactive Drugs. 2022 Jan 9;:1-8
pubmed: 35000559
Front Hum Neurosci. 2016 Jun 14;10:269
pubmed: 27378878
Curr Opin Psychol. 2019 Aug;28:60-64
pubmed: 30481655
J Psychopharmacol. 2017 Jul;31(7):841-850
pubmed: 28095732
Am J Prev Med. 2011 Jan;40(1):67-71
pubmed: 21146770
J Psychopharmacol. 2022 Jan;36(1):12-19
pubmed: 34053342
Hypertension. 2021 May 5;77(5):1510-1516
pubmed: 33677982
J Psychopharmacol. 2022 Jan;36(1):31-45
pubmed: 34983255
J Sci Study Relig. 2012 Dec;51(4):721-737
pubmed: 23316089
Psychopharmacology (Berl). 2018 Oct;235(10):2979-2989
pubmed: 30105399
Sci Rep. 2021 Jul 13;11(1):14427
pubmed: 34257396

Auteurs

Otto Simonsson (O)

Center for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institute, Tomtebodavägen 18A, 171 77, Stockholm, Sweden.
Department of Sociology, University of Oxford, Oxford, 42-43 Park End Street, OX1 1JD, UK.
Department of Health Behavior, School of Public Health, University of Alabama at Birmingham, 1665 University Boulevard, 35233, Birmingham, AL, USA.

Peter S Hendricks (PS)

Department of Health Behavior, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA.

Richard Chambers (R)

Monash Centre for Consciousness & Contemplative Studies, Monash University, Melbourne, VIC, Australia.

Walter Osika (W)

Center for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.

Simon B Goldberg (SB)

Department of Counseling Psychology, University of Wisconsin-Madison, Madison, WI, USA.

Classifications MeSH